Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
Business Wire•27/07/2026•07:30 ET
0
Whiz Insights
Get started
Create a free account to read the full story.